Search Results
Your search for all items matches 34736 pages
Showing 16201 - 16250CYP2D6 Genotypes, Endoxifen Levels, and Clinical Outcome in Early-Stage Breast Cancer Treated With Adjuvant Tamoxifen
In a Dutch-Belgian study (CYPTAM) reported in the Journal of Clinical Oncology, Sanchez-Spitman et al found no associations between CYP2D6 genotypes or levels of endoxifen (active metabolite of tamoxifen) and clinical outcomes in patients receiving adjuvant tamoxifen for early-stage breast cancer....
Effect of Peer Review Within a Cancer Care Network on Use of Hypofractionated Radiotherapy for Early-Stage Breast Cancer
In a study reported in the Journal of Oncology Practice, Ganju et al found that implementation of a cancer care network–wide peer review process aimed at standardizing treatment resulted in increasing use of hypofractionated radiotherapy in early-stage breast cancer at community-based...
Avelumab in Recurrent or Refractory Ovarian Cancer
In phase Ib results from the JAVELIN Solid Tumor Trial reported in JAMA Oncology, Disis et al found that avelumab produced durable responses in some patients with recurrent or refractory ovarian cancer. In the study, an expansion cohort of 125 women with advanced disease who had received...
HLA Mismatch and Skin Cancer Risk After Organ Transplant
Data on the risk factors for the development of skin cancer after a solid organ transplant are limited. In a retrospective cohort study, researchers sought to determine the relationship between human leukocyte antigen (HLA) mismatch and risk of skin cancer after transplant. Their findings were...
American Lung Association's State of Tobacco Control Report Released
According to the American Lung Association’s recently released 2019 State of Tobacco Control report, states and the federal government have not taken meaningful action in establishing policies to prevent and reduce tobacco use, the nation's leading cause of preventable death and disease. ...
Clonal MET Amplification and Tyrosine Kinase Inhibitor Treatment Outcome in EGFR-Mutant NSCLC
In a Singaporean study reported in the Journal of Clinical Oncology, Lai et al found that tyrosine kinase inhibitor treatment outcome did not differ according to mesenchymal epithelial transition factor (MET)-high vs MET-low status in treatment-naive, EGFR-mutant non–small cell lung cancer...
Quality of Life in Men Living With Advanced and Localized Prostate Cancer
In a population-based study reported in The Lancet Oncology, Downing et al found little difference in health-related quality of life (HRQOL) between men with advanced vs localized prostate cancer. Sexual function problems were common among all patients—and often not addressed—and use of ...
Obesity-Related Cancers Rising in Young Adults in the United States
A new study has found rates are increasing for 6 of 12 cancers related to obesity in younger adults in the United States, with steeper increases in progressively younger ages and successively younger generations. The study, published by Sung et al in The Lancet Public Health, also looked at rates...
New Standards for Safe Handling of Hazardous Drugs Focus on Developing Evidence-Based Measures
ASCO recently published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology.1 ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is...
Taking a Stand: How ASCO Develops Policy Guidance and Position Statements
As a global thought leader in the spheres of cancer care and research, ASCO recognizes the importance of taking a position on certain key issues affecting its members and the patients they serve. As a result, ASCO will, on occasion, release policy guidance and position statements when existing...
New JOP Article Highlights Challenges Oncologists Face Due to a Lack of Interoperability, and How CancerLinQ® Can Help
A new article in the Journal of Oncology Practice (JOP)1 looks at how ASCO’s commitment to CancerLinQ® can lead to improvements in the interoperability of electronic health records (EHRs). The article, by Wendy S. Rubinstein, MD, PhD, FACP, FACMG, Deputy Medical Director of CancerLinQ LLC,...
New ASCO Answers Fact Sheet: When the Doctor Says ‘Cancer’
People diagnosed with cancer often say they were stunned when they heard the news of their diagnosis, and were unable to process what their health-care provider said afterward. Give your patients easy-to-understand information they can take home with them. When the Doctor Says “Cancer” is a 1-page...
Leave a Legacy of Hope
By including a planned gift to ASCO’s Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for patients with cancer years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and...
Clinical Cancer Advances 2019: ASCO Names Advance of the Year, Debuts Research Priorities for the Cancer Community
In the release of its annual report on progress against cancer, Clinical Cancer Advances 2019, ASCO recognized progress in treating rare cancers as the Advance of the Year. The report catalogs a year’s worth of remarkable research advancements, reinforces the need for continued federal research...
Expert Point of View: Steven Gore, MD, Eyten Stein, MD, and Elihu H. Estey, MD
In discussions after these presentations, several points were made by several experts. To begin, Steven Gore, MD, Director of Hematologic Malignancies at Yale Medical School, called the study of venetoclax plus 10-day decitabine “very important,” but he raised the issue of appropriate dosing. He...
Data Mount for Venetoclax as Add-on Therapy in Acute Myeloid Leukemia
The benefit of adding venetoclax to a hypomethylating agent or low-dose cytarabine in the front-line treatment of acute myeloid leukemia (AML) was evident from a number of studies reported at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition (see Table 1). For elderly...
Expert Point of View: Ravi Vij, MD and Saad Usmani, MD
Ravi Vij, MD, Professor of Medicine at Washington University School of Medicine, St. Louis, and Saad Usmani, MD, Director of Plasma Cell Disorders at Levine Cancer Institute, Charlotte, North Carolina, spoke to The ASCO Post about the studies presented on chimeric antigen receptor (CAR) T-cell...
Multiple Myeloma Pipeline Filled With CAR T-Cell Therapies
The burgeoning pipeline of chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) in multiple myeloma was on full display at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. A bispecific antibody also made its debut in this busy...
Expert Point of View: Mrinal S. Patnaik, MBBS and David P. Steensma, MD
Mrinal S. Patnaik, MBBS, Associate Professor of Internal Medicine and Oncology and a consultant in hematology at the Mayo Clinic, Rochester, commented on the MEDALIST trial for The ASCO Post. “Given its unique mode of action, relative ease of administration, and excellent tolerability,...
Luspatercept May Reduce the Need for Transfusion in Lower-Risk Myelodysplastic Syndromes
In the randomized, double-blind, phase III MEDALIST trial, the experimental drug luspatercept significantly reduced the need for frequent red blood cell transfusions in patients with lower-risk myelodysplastic syndromes (MDS) and ring sideroblasts. With luspatercept, 37.9% remained transfusion-free ...
Expert Point of View: Virginia Kaklamani, MD and Wendy A. Woodward, MD
At a press conference held during the 2018 San Antonio Breast Cancer Symposium, moderator Virginia Kaklamani, MD, said that partial-breast irradiation is underutilized in the United States for women with breast cancer. Dr. Kaklamani is Professor of Medicine at The University of Texas at San...
Small Differences Found in Breast Cancer Recurrence With Partial-Breast vs Whole-Breast Irradiation
Partial-breast irradiation delivered over 5 to 10 days did not meet noninferiority criteria compared with whole-breast irradiation given over 5 to 7 weeks, according to 10-year results of the large NRG (NSABP B-39/RTOG 0413) trial presented at the 2018 San Antonio Breast Cancer Symposium.1 However, ...
Genomic Classification of Lung Cancers Diagnosed in Patients From Appalachian Kentucky
Squamous cell carcinoma of the lung represents approximately one-quarter (26.4%) of all lung cancers diagnosed in Appalachian Kentucky, where death from lung cancer is higher than the national average. Researchers sought to characterize genetic alterations specifically found in lung squamous cell...
Enhancing Patient Outcomes After Whipple Procedure
Pancreaticoduodenectomy, or the Whipple procedure, is one of the most complex abdominal surgeries, and is commonly prescribed as a first line of therapy for cancer located within the pancreatic head. Investigators reported that following a 5-day accelerated recovery pathway after surgery helped to...
Selected Abstracts From the San Antonio Breast Cancer Symposium
Each year, The ASCO Post asks Jame Abraham, MD, FACP, Director of the Breast Oncology Program at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most important research presented at the 2018 San Antonio Breast Cancer ...
Clinical Significance of Indeterminate Pulmonary Nodules at Diagnosis in Pediatric Rhabdomyosarcoma
In a study reported in the Journal of Clinical Oncology, Vaarwerk et al found that presence of indeterminate pulmonary nodules at diagnosis of pediatric rhabdomyosarcoma did not adversely affect treatment outcome in otherwise localized disease. The study involved 316 patients from the European...
World Cancer Day 2019: Emphasis on Early Detection
World Cancer Day 2019—February 4—highlights the need for urgent action to increase early-stage cancer detection, screening, and diagnosis to significantly improve patients’ chances of survival. Taking place with the theme of “I Am and I Will,” World Cancer...
Ramucirumab in Sorafenib-Pretreated Patients With Advanced HCC and Increased α-Fetoprotein
In the phase III REACH-2 trial reported in The Lancet Oncology, Zhu et al found that ramucirumab improved overall and progression-free survival vs placebo in patients with advanced hepatocellular carcinoma (HCC) and increased α-fetoprotein levels who had previously received sorafenib. Study...
Expert Point of View: Harry H. Yoon, MD
Harry H. Yoon, MD, Associate Professor of Oncology at the Mayo Clinic, Rochester, Minnesota, the invited discussant of the study presented by Janjigan et al, commented on the strong rationale for combining an anti-HER2 agent, anti–programmed cell death protein 1 (PD-1) agent, and chemotherapy....
First-Line Trastuzumab Plus Pembrolizumab Shows Efficacy in Patients With Metastatic Esophagogastric Cancer
When added to first-line chemotherapy in patients with untreated metastatic HER2-positive esophageal, gastroesophageal junction, and gastric adenocarcinoma, the combination of pembrolizumab and trastuzumab produced responses in 87% of patients, with 100% of patients experiencing disease control and ...
Expert Point of View: Martine Extermann, MD, PhD
As invited discussant of the GAMMA-1 trial, Martine Extermann, MD, PhD, of Moffitt Cancer Center and Research Institute, Tampa, Florida, first commented on the “teaser” in the findings—the potential for benefit of andecaliximab in older patients. “The drug works better in older patients. As a...
Andecaliximab in Untreated Gastric or Gastroesophageal Junction Cancer
The large phase III GAMMA-1 trial failed to replicate the encouraging findings from a previous smaller study of andecaliximab plus chemotherapy in untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma, according to Manish A. Shah, MD, of Weill Cornell Medicine/New York...
Essential Elements of an Effective Clinical Trials System: Business and Mission
Clinical trials aimed to improve health and quality of life are the cornerstone of progress in medicine. Support comes from academic medical centers, philanthropy, the National Institutes of Health (NIH), industry, or combinations thereof. Clinical trials need to be hypothesis-driven and address...
Progress With ALK Inhibitors: When Will We Consider ALK-Positive Lung Cancer a ‘Chronic Disease’?
As reported by Solomon et al in The Lancet Oncology1 and reviewed in this issue of The ASCO Post, results from a global phase II study of the third-generation ALK inhibitor lorlatinib showed a high overall response rate and high intracranial response rate for patients with advanced ALK-positive...
Expert Point of View: Harry H. Yoon, MD
KEYNOTE-181’s invited discussant, Harry H. Yoon, MD, Associate Professor of Oncology at the Mayo Clinic, Rochester, Minnesota, said the findings have a “potentially immediate clinical impact” for second-line treatment of esophageal cancer, including esophageal squamous cell carcinoma and Siewert...
KEYNOTE-181: Pembrolizumab vs Chemotherapy in Second-Line Treatment of Advanced Esophageal Cancer
In the global phase III KEYNOTE-181 trial, pembrolizumab as second-line therapy for advanced esophageal cancer did not improve overall survival in the whole population, vs chemotherapy, but did improve survival for patients with strong expression of programmed cell death ligand 1 (PD-L1),...
Lung-MAP Precision Medicine Trial Expands
The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), is undergoing a major expansion to include patients with all non–small cell lung cancers (NSCLCs). The trial previously tested treatments for people ...
How Effective Is Talimogene Laherparepvec Injection in Metastatic Melanoma?
Injection of a genetically modified virus that induces the body’s own immune cells to attack metastatic melanoma effectively treated almost 40% of patients with tumors that could not be surgically removed, according to findings published by Louie et al in the Journal of the American...
Trial of Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma
In a phase III trial reported in the Journal of Clinical Oncology, Stadtmauer and colleagues found that second autologous hematopoietic cell transplantation (AHCT) or RVD (lenalidomide, bortezomib, dexamethasone) consolidation as post-AHCT interventions did not improve outcomes vs single...
Nivolumab or Nivolumab Plus Ipilimumab in Relapsed Malignant Pleural Mesothelioma
In a French phase II trial reported in The Lancet Oncology, Scherpereel et al found evidence of activity with nivolumab or the combination of nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma. Study Details In the open-label, noncomparative trial, 125 patients...
Treatment Outcomes for Children With Hypodiploid Acute Lymphoblastic Leukemia
In a retrospective study reported in the Journal of Clinical Oncology, Pui et al found that minimal residual disease (MRD)-negative status, high hypodiploidy with 44 chromosomes, and MRD-stratified treatment were associated with improved outcomes among children treated for newly diagnosed...
HPV Testing Using Self-Collected vs Clinician-Collected Samples for the Detection of Cervical Intraepithelial Neoplasia
In a Dutch study (IMPROVE) reported in The Lancet Oncology, Polman et al found that human papillomavirus (HPV) testing with a clinically validated polymerase chain reaction (PCR)–based assay had similar accuracy using self-collected vs clinician-collected samples in detecting cervical...
Avelumab in Previously Treated Advanced Unresectable Mesothelioma
In a phase Ib trial reported in JAMA Oncology, Hassan et al found that the anti–programmed cell death ligand 1 antibody avelumab produced durable responses and a high rate of disease control in some patients with advanced unresectable mesothelioma progressing after platinum and pemetrexed...
FDA Expands Pemetrexed Label With Combination of Pembrolizumab and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous NSCLC
Today, the U.S. Food and Drug Administration (FDA) granted approval for a new indication for pemetrexed (Alimta) for injection in combination with pembrolizumab (Keytruda) and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell...
ASCO Clinical Cancer Advances 2019 Names Advance of the Year: Progress in Treating Rare Cancers
Over the past year, major research advances provided new treatment options for patients with rare, difficult-to-treat cancers. In recognition of these achievements, ASCO named “Progress in Treating Rare Cancers” as the Advance of the Year. To continue the forward momentum, ASCO also...
FDA Pipeline: Updates on Treatments in NSCLC and Lymphomas, Plus New Dosimetry Software
The U.S. Food and Drug Administration (FDA) recently granted the following application, designations, and clearance: sBLA for Atezolizumab Plus Chemotherapy for First-Line Treatment of Metastatic, Nonsquamous NSCLC On January 17, the FDA accepted a supplemental biologics license application...
Effectiveness of EsophaCap Tool in the Diagnosis of Barrett’s Esophagus
Barrett’s esophagus is the only known precursor of esophageal adenocarcinoma. Although endoscopy and biopsy are standard methods for diagnosing Barrett’s esophagus, their high cost and risk limit their use as a screening modality. Researchers sought to develop a screening method based...
Prevalence of Infection With HBV, HBC, and HIV in Patients With Newly Diagnosed Cancer
In a prospective cohort study reported in JAMA Oncology, Ramsey et al identified the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection in patients with newly diagnosed cancer and found that a substantial proportion were unaware of...
Standard Site-Specific Therapy Based on Gene-Expression Profiling vs Empirical Chemotherapy for Cancer of Unknown Primary
In a Japanese phase II trial reported in the Journal of Clinical Oncology, Hayashi et al found that standard site-specific treatment based on gene-expression profiling was not associated with better outcomes vs empirical paclitaxel and carboplatin in patients with cancer of unknown primary site....
Racial Differences in Time to Breast Cancer Surgery and Survival in the U.S. Military Health System
In a retrospective cohort study reported in JAMA Surgery, Eaglehouse et al found that time to breast cancer surgery was delayed for non-Hispanic black vs non-Hispanic white women in the Military Health System but that this difference did not account for poorer overall survival in non-Hispanic black ...
